Close

Tocilizumab

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Summary Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 […]

Read More

Tocilizumab in Covid-19 Pneumonia

Severe Covid-19 pneumonia occurs in approximately 15% of patients and is associated with high mortality. Case reports and observational studies have suggested that treatment with tocilizumab causes rapid fever reduction and reduces need for oxygen support. New research findings are summarized in a short video. Treating Severe Covid-19 Severe Covid-19 […]

Read More